Global HER2 Positive Breast Cancer Trial Opens in NJ
New Jersey's only NCI-designated Comprehensive Cancer Center is taking part in a worldwide clinical trial targeting HER2 positive breast cancer, which accounts for up to 25 percent of all breast cancers.